#New Zealand #Auckland #Aroa Biosurgery #Myriad Matrix #MASTRR study

Aroa Biosurgery's Latest Study on Myriad™

Aroa Biosurgery Limited has published groundbreaking findings from their ongoing research, emphasizing the effectiveness of Myriad™, an innovative bioscaffold, in trauma and acute care surgery. This publication, stemming from the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), appears in the esteemed Journal of Trauma and Injury and showcases the comprehensive data gathered from the largest prospective study of its kind.

Overview of the Study

The MASTRR study is unique, as it is a multicenter observational study that aims to collect data on how a bioscaffold can be used in complex reconstruction. To date, over 450 patients have been recruited, making it a significant contributor to the understanding of trauma care. The focus of this particular analysis is the research titled, "Vascularized Tissue Coverage of Trauma and Acute Care Surgery Defects with Ovine Forestomach Matrix Interim Results of a Prospective Multicenter Study." This evaluation delves into the safety and effectiveness of Myriad Matrix and Myriad Morcells during trauma procedures.

Key Findings

The study reported on 49 patients who experienced a total of 61 defects, treated across four level one trauma centers in the United States. Given that these centers deal with complex trauma cases involving substantial wound areas that are often contaminated, the findings are particularly noteworthy. Remarkably, the results indicate that wounds treated with Myriad achieved full vascularized tissue coverage in a median timeframe of just 22.5 days, frequently requiring only one application of the product. Notably, there were no complications related to the device noted in the study, further substantiating its safety profile.

Additionally, the study provided a comparative analysis of the performance and costs of Myriad against other standard bioscaffolds utilized in trauma reconstruction. The results revealed that Myriad is more cost-effective per cm and yielded comparable or superior clinical outcomes compared to its competitors.

Insights from Professionals

Dr. Michael Cormican, a participating study author and trauma surgeon, highlighted the value of this prospective data. He stated, "This prospective data provides validation to what we were already seeing in surgical practice, that Myriad offers a cost-effective solution to improve coverage and healing of complex trauma defects without adding risk to the patient."

Aroa’s CEO, Brian Ward, expressed confidence in the implications these findings hold for trauma care, stating, "We're very pleased to see this third study published from our ongoing MASTRR study. The evidence underscores both the effectiveness of Myriad in complex trauma procedures, and its potential to lower the total cost of care for hospitals. With over 140,000 trauma procedures performed annually in the US, and a total addressable market of approximately US$450 million, this represents a sizable growth opportunity for Aroa."

Conclusion

The publication of this study further fortifies the credibility of Aroa's innovative approaches in managing complex wounds. The findings align with over 116 peer-reviewed studies showcasing the versatility and value of AROA ECM™ in various surgical applications, which remarkably enhance patient outcomes and foster cost savings for healthcare providers.

Aroa Biosurgery dedicates its efforts to improving patient care through advanced medical technology. Established in 2008 and headquartered in Auckland, New Zealand, the company has developed a robust technological platform focused on regenerative healing. Aroa’s products have been implemented in numerous procedures worldwide, showcasing their effectiveness and reliability. The future of trauma care appears increasingly hopeful as further research validates the utility of Aroa's solutions for complex surgical challenges.